Senesco completes first cohort of patients in Phase 1b/2a multiple myeloma trial

SNS01-T met the criteria for Stable Disease in two of the three evaluable patients that comprised first cohort. No drug-related serious adverse events or dose limiting toxicities were recorded for any patients.

The Data Review Committee (DRC) advised Senesco that SNS01-T was safe and well tolerated and is appropriate to proceed with cohort 2 to escalate the dose level to 0.05mg/kg, a four-fold increase.

Senesco chairman Harlan Waksal said the promising result that we observed in the first patient has been confirmed by a similar effect, Stable Disease, in another patient.

"We are looking forward to seeing the effect of increasing the dose level in the next group of patients," Waksal added.

In two of the three patients in the first cohort, disease had not progressed on treatment, based on several criteria including the monoclonal protein, and was considered stable at week three and week six, the end of the dosing regimen.

Three patients were withdrawn from the open-label, multiple-dose, dose-escalation study due to disease progression before completing treatment. One of the responding patients has continued to have Stable Disease at week 10, a month after the end of treatment with SNS01-T.